The diagnostics startup is developing a testing platform that uses digital imaging and signal processing for pathogen identification and susceptibility determination.

Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.

Demand remains low, but lab stakeholders said the industry is significantly better prepared to meet a spike in H5N1 testing ...

Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers from biopsy images will be combined with Tempus' real-world data.

Total revenues were $3.33 billion, up from $3.03 billion in the same quarter last year and slightly above the consensus Wall Street estimate of $3.31 billion.

The digital pathology software developer is raising funding that would help it to increase its headcount and support its Aiosyn Mitosis Breast application.

The Foundation Medicine next-generation sequencing-based panels use Fulgent's technology platform and will analyze genes associated with hereditary cancers.

NEW YORK — MRC Holland said on Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR ...

Qiagen said the intellectual property in question covers technologies used in its QuantiFeron latent tuberculosis assays.

Cubit Diagnostics announced on Tuesday that it has been awarded $2.6 million by the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) Tech program. The funding will enable the ...

Abbott also currently offers the FDA-cleared molecular Alinity M STI assay to detect and differentiate between Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma ...